Deals
Deals dated after 30 September 2026 are still being collected.
Columns
18 of 18 deals
| Advisers | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Sep 2026 | ADARx Pharmaceuticals | – | – | IPO | Bookrunner | Announced | 446.3 | Biotech+1 | J.P. Morgan (lead manager)Morgan Stanley (lead manager)TD Securities (lead manager)UBS (lead manager)Cooley (issuer)Latham & Watkins (lead manager) | ADARx Pharmaceuticals IPO |
| Sep 2026 | ADARx Pharmaceuticals | – | – | Placement | Placement agent to the lead managers | Announced | 89.0 | Biotech+1 | J.P. Morgan (lead manager)Morgan Stanley (lead manager)TD Securities (lead manager)UBS (lead manager) | ADARx Pharmaceuticals placement |
| Aug 2026 | Amylyx Pharmaceuticals | – | – | Follow-on offering | Bookrunner | Announced | 575.2 | Biotech+1 | Goodwin (issuer)Leerink Partners (lead manager)Morgan Stanley (lead manager)Guggenheim Securities (lead manager) | Amylyx Pharmaceuticals equity raising |
| Aug 2026 | Werewolf Therapeutics | – | – | Placement | Placement agent to the lead managers | Announced | 150.0 | Biotech+2 | Leerink Partners (lead manager)Piper Sandler (lead manager)Cantor Fitzgerald (lead manager)Wells Fargo Securities (lead manager)Latham & Watkins (lead manager) | Werewolf Therapeutics placement |
| Aug 2026 | Attovia Therapeutics | – | – | IPO | Underwriter and bookrunner | Listed | 289.0 | Biotech+1 | Morgan Stanley (lead manager)Leerink Partners (lead manager)Citi (lead manager)RBC Capital Markets (lead manager)Fenwick & West (issuer)Cooley (lead manager) | Attovia Therapeutics IPO |
| Aug 2026 | BlossomHill Therapeutics | – | – | IPO | Underwriter | Listed | 150.0 | Biotech+2 | J.P. Morgan (lead manager)Leerink Partners (lead manager)Guggenheim Securities (lead manager)H.C. Wainwright & Co. (lead manager)Cooley (issuer)Latham & Watkins (lead manager) | BlossomHill Therapeutics IPO |
| Jul 2026 | Apnimed | – | – | IPO | Underwriter | Listed | 192.0 | Biotech+1 | BofA Securities (lead manager)Evercore (lead manager)Cantor Fitzgerald (lead manager)Goodwin (issuer)Cleary Gottlieb Steen & Hamilton (lead manager) | Apnimed IPO |
| Jul 2026 | Caldera Therapeutics | – | – | Placement | Placement agent to the lead managers | Announced | 278.0 | Biotech+1 | Jefferies (lead manager)TD Securities (lead manager)Guggenheim Securities (lead manager)UBS (lead manager)Cooley (lead manager) | Caldera Therapeutics placement |
| Jul 2026 | Research Alliance Corporation III | – | – | Placement | Placement agent to the lead managers | Announced | 100.0 | Biotech+2 | Leerink Partners (lead manager)UBS (lead manager)Wells Fargo Securities (lead manager)Kirkland & Ellis (lead manager) | Research Alliance Corporation III placement |
| Jul 2026 | Jasper Therapeutics | – | – | Placement | Placement agent to the lead managers | Announced | 132.0 | Biotech+1 | Piper Sandler (lead manager) | Jasper Therapeutics placement |
| Jun 2026 | JATT II Acquisition Corp | – | – | Placement | Placement agent to the lead managers | Announced | 225.0 | Biotech+1 | Guggenheim Securities (lead manager)Cantor Fitzgerald (lead manager)Davis Polk (lead manager) | JATT II Acquisition Corp placement |
| Jun 2026 | Parabilis Medicines | – | – | IPO | Bookrunner | Listed | 670.0 | Biotech+2 | Leerink Partners (lead manager)BofA Securities (lead manager)Evercore (lead manager)Guggenheim Securities (lead manager)Goodwin (issuer)Covington & Burling (lead manager) | Parabilis Medicines IPO |
| May 2026 | Orphai Therapeutics | – | Quince Therapeutics | Acquisition | Financial adviser to Quince Therapeutics (acquirer) | Completed | – | Biotech+2 | Dorsey & Whitney (buy-side)Cooley (sell-side)Oppenheimer & Co. (buy-side)Gibson Dunn (buy-side) | Quince Therapeutics acquisition of Orphai Therapeutics |
| May 2026 | Quince Therapeutics | – | – | Placement | Placement agent to the lead managers | Announced | 115.0 | Biotech+2 | Gibson Dunn (lead manager)EvercoreCantor Fitzgerald | Quince Therapeutics placement |
| Apr 2026 | Obsidian Therapeutics | – | – | Placement | Placement agent to the lead managers | Completed | 350.0 | Biotech+2 | Leerink Partners (lead manager)TD Securities (lead manager)Piper Sandler (lead manager)William Blair (lead manager)Mintz (lead manager)GoodwinSidley Austin (issuer) | Obsidian Therapeutics placement |
| Feb 2026 | Perspective Therapeutics | – | – | Follow-on offering | Bookrunner | Announced | 175.0 | Radiopharmaceuticals+2 | Piper Sandler (lead manager)UBS (lead manager)Oppenheimer & Co. (lead manager)Truist Securities (lead manager) | Perspective Therapeutics equity raising |
| Jul 2025 | Cyabra Strategy | – | Trailblazer Merger Corporation I | Merger | Financial adviser | Completed | 106.0 | Cybersecurity+1 | Roth Capital Partners (buy-side)Loeb & Loeb (buy-side)Sullivan & Worcester (buy-side)Lowenstein Sandler (sell-side)Goldfarb Gross Seligman (sell-side) | Trailblazer Merger Corporation I and Cyabra Strategy merger |
| Mar 2025 | Brainomix | – | Parkwalk Advisors, Boehringer Ingelheim Venture Fund | Series C | Supported the funding round to the issuer | Completed | 17.5 | Medtech+2 | Brainomix Series C |
Activity
By announcement date; raisings and IPOs by their own date.
Sector of the business bought or funded.
Disclosed value in US dollars.